Mylan

991 articles about Mylan

• Mylan Inc.'s Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment

  8/18/2009

• US FDA Clears Key Mylan Inc. Plant, Closes Probe

  8/14/2009

• Mylan Inc. Receives FDA Approval for Generic Version of Migraine Treatment Imitrex(R)

  8/11/2009

• President Clinton, Pfizer Inc., and Mylan Inc. Announce New Agreements to Lower Prices of Medicines for Patients with Drug-Resistant HIV in Developing Countries

  8/6/2009

• FDA Expects to Wrap up Mylan Inc. Probe Within Weeks

  8/4/2009

• Mylan Inc. Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

  7/30/2009

• Mylan Inc. Reshuffles Management; Heather Bresch Promoted To President, Rajiv Malik Appointed COO

  7/29/2009

• Mylan Inc. Reports That the FDA Determined That All Accusations Were Unfounded

  7/28/2009

• Mylan Inc. Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality

  7/27/2009

• Mylan Inc. Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol

  7/20/2009

• Mylan Inc. Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R) Begins Shipment of Products

  7/16/2009

• Mylan Inc. Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)

  7/7/2009

• Mylan Inc. Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast

  7/6/2009

• Mylan Inc. Announces Strategic Collaboration with BioCon Limited to Enter the Global Generic Biologics Market

  6/29/2009

• Mylan Inc. Receives FDA Approval for Additional Strength of Generic Restoril(R)

  6/18/2009

• Mylan Inc. Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period

  6/3/2009

• Mylan Inc.'s Chief Operating Officer to Testify Before Congress Concerning Patent Settlements

  6/2/2009

• Mylan Inc. Announces Successful Matrix Delisting Offer

  6/1/2009

• Mylan Inc. Receives Tentative FDA Approval for Generic Version of Singulair(R)

  5/29/2009

• Mylan Inc. Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)

  5/7/2009